|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:activeIngredient
|
gptkb:lopinavir
gptkb:ritonavir
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AR10
|
|
gptkbp:brand
|
gptkb:Kaletra
|
|
gptkbp:CASNumber
|
gptkb:192725-17-0_(lopinavir/ritonavir)
|
|
gptkbp:combinationTherapy
|
yes
|
|
gptkbp:contains
|
gptkb:lopinavir
gptkb:ritonavir
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:developedBy
|
gptkb:Abbott_Laboratories
|
|
gptkbp:drugClass
|
protease inhibitor
|
|
gptkbp:eliminationHalfLife
|
5-6 hours
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kaletra
|
|
gptkbp:indication
|
gptkb:HIV-2_infection
HIV-1 infection
|
|
gptkbp:interactsWith
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:St._John's_wort
phenobarbital
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:AbbVie
|
|
gptkbp:mechanismOfAction
|
inhibits HIV protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 14 days old
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults
children
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
hyperglycemia
hyperlipidemia
|
|
gptkbp:storage
|
room temperature
refrigeration (oral solution)
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Lopinavir
gptkb:lopinavir
gptkb:lopinavir/ritonavir
|
|
gptkbp:bfsLayer
|
7
|